CD8A and melanoma: Their results showed that the TLR-3 ligand-DEXs vaccine (OVA + poly I:C) stimulated higher antigen-specific CD8+ T-cell proliferation and effector functions and increased the population of TNFα+CD4+ T cells in the lymph nodes of vaccinated mice with melanoma compared to other vaccine formulations 19 days after priming.